NO994967L - Gene delivery vehicles expressing the apoptosis-inducing proteins VP2 and / or apoptin - Google Patents
Gene delivery vehicles expressing the apoptosis-inducing proteins VP2 and / or apoptinInfo
- Publication number
- NO994967L NO994967L NO994967A NO994967A NO994967L NO 994967 L NO994967 L NO 994967L NO 994967 A NO994967 A NO 994967A NO 994967 A NO994967 A NO 994967A NO 994967 L NO994967 L NO 994967L
- Authority
- NO
- Norway
- Prior art keywords
- apoptosis
- gene delivery
- delivery vehicles
- apoptin
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to gene delivery vehicles which comprise nucleic acid molecules encoding apoptosis-inducing proteins VP2 and/or apoptin (VP3) like activity. VP2 and VP3 are viral proteins of the Chicken Anaemia Virus. Also, the invention relates to anti-tumor therapies. Infection of various human tumor cells with the gene delivery vehicles of the invention will result in the induction of apoptosis in tumor cells and much reduced apoptosis, if at all, in normal diploid, non-transformed/non-malignant cells. Also the invention relates to the diagnosis of cancer, and related forms of hyperplasia, metaplasia and dysplasia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97201121A EP0872552A1 (en) | 1997-04-15 | 1997-04-15 | A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or Apoptin |
EP97203595A EP0878546A1 (en) | 1997-04-15 | 1997-11-18 | A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin |
PCT/NL1998/000213 WO1998046760A1 (en) | 1997-04-15 | 1998-04-15 | A gene delivery vehicle expressing the apoptosis-inducing proteins vp2 and/or apoptin |
Publications (2)
Publication Number | Publication Date |
---|---|
NO994967D0 NO994967D0 (en) | 1999-10-12 |
NO994967L true NO994967L (en) | 1999-12-15 |
Family
ID=26146368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO994967A NO994967L (en) | 1997-04-15 | 1999-10-12 | Gene delivery vehicles expressing the apoptosis-inducing proteins VP2 and / or apoptin |
Country Status (17)
Country | Link |
---|---|
EP (2) | EP0878546A1 (en) |
JP (1) | JP2001521387A (en) |
KR (1) | KR100528755B1 (en) |
AT (1) | ATE275200T1 (en) |
AU (1) | AU750162B2 (en) |
BR (1) | BR9808542A (en) |
CA (1) | CA2286165C (en) |
CZ (1) | CZ299963B6 (en) |
DE (1) | DE69825978T2 (en) |
DK (1) | DK0975764T3 (en) |
ES (1) | ES2227822T3 (en) |
NO (1) | NO994967L (en) |
NZ (1) | NZ500012A (en) |
PL (1) | PL196607B1 (en) |
PT (1) | PT975764E (en) |
SK (1) | SK285724B6 (en) |
WO (1) | WO1998046760A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9811163A (en) * | 1997-08-12 | 2000-07-25 | Leadd Bv | Processes to determine the transformation capacity of a possible transforming agent, the predisposition of a cell to become a tumor cell and an individual to hereditary types of cancer, and a gene mutation showing oncogenic and / or transforming activity in a cell, use of a nucleic acid encoding apoptin or a fragment or functional derivative thereof, and diagnostic test kit |
AU2004233486B2 (en) * | 1999-01-11 | 2007-09-13 | Leadd B.V. | Use of apoptosis inducing agents in the treatment of (auto)immune diseases |
JP2003500336A (en) * | 1999-01-11 | 2003-01-07 | レアト ベー.フェー. | Use of apoptosis inducers in the treatment of (auto) immune diseases |
EP1081226A1 (en) * | 1999-09-02 | 2001-03-07 | Leadd B.V. | Apoptin-associating protein |
JP2003510030A (en) * | 1999-09-02 | 2003-03-18 | レアト ベー.フェー. | Apoptin-related protein |
AU784723B2 (en) * | 1999-12-10 | 2006-06-01 | Leadd B.V. | Apoptin-associating protein |
PT1377667E (en) * | 2001-03-30 | 2009-03-13 | Leadd Bv | Fusion proteins for specific treatment of cancer and auto-immune diseases |
KR100561985B1 (en) | 2004-07-03 | 2006-03-22 | 고려대학교 산학협력단 | Cancer-specific apoptin-expression cassette and adenovirus expression vector comprising the same |
KR100877824B1 (en) | 2005-11-11 | 2009-01-12 | 한국생명공학연구원 | E2EPF ubiquitin carrier protein-von Hippel-Lindau interaction and uses of thereof |
CN109111527B (en) * | 2018-08-03 | 2022-03-15 | 沈阳金石生物制药有限公司 | GIP34-VP3 fusion protein for targeted specific induction of tumor cell apoptosis and preparation method and application thereof |
CN109266714A (en) * | 2018-10-12 | 2019-01-25 | 广州医科大学 | A kind of detection method of circulating tumor cell |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL9301272A (en) * | 1993-07-20 | 1995-02-16 | Aesculaap Bv | Chicken Anemia Virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or coding sequences of that virus. |
NL9002008A (en) * | 1990-09-12 | 1992-04-01 | Stichting Centr Diergeneeskund | RECOMBINANT DNA AND RNA AND PRODUCTS DERIVED THEREFROM. |
FR2732348B1 (en) * | 1995-03-31 | 1997-04-30 | Rhone Poulenc Rorer Sa | CONDITIONAL EXPRESSION SYSTEM |
-
1997
- 1997-11-18 EP EP97203595A patent/EP0878546A1/en not_active Withdrawn
-
1998
- 1998-04-15 CZ CZ0349399A patent/CZ299963B6/en not_active IP Right Cessation
- 1998-04-15 DE DE69825978T patent/DE69825978T2/en not_active Expired - Fee Related
- 1998-04-15 EP EP98914146A patent/EP0975764B1/en not_active Expired - Lifetime
- 1998-04-15 CA CA002286165A patent/CA2286165C/en not_active Expired - Fee Related
- 1998-04-15 WO PCT/NL1998/000213 patent/WO1998046760A1/en not_active Application Discontinuation
- 1998-04-15 KR KR10-1999-7009550A patent/KR100528755B1/en not_active IP Right Cessation
- 1998-04-15 ES ES98914146T patent/ES2227822T3/en not_active Expired - Lifetime
- 1998-04-15 SK SK1428-99A patent/SK285724B6/en not_active IP Right Cessation
- 1998-04-15 JP JP54377198A patent/JP2001521387A/en active Pending
- 1998-04-15 AT AT98914146T patent/ATE275200T1/en not_active IP Right Cessation
- 1998-04-15 DK DK98914146T patent/DK0975764T3/en active
- 1998-04-15 PT PT98914146T patent/PT975764E/en unknown
- 1998-04-15 AU AU68563/98A patent/AU750162B2/en not_active Ceased
- 1998-04-15 BR BR9808542-5A patent/BR9808542A/en not_active Application Discontinuation
- 1998-04-15 PL PL336312A patent/PL196607B1/en unknown
- 1998-04-15 NZ NZ500012A patent/NZ500012A/en unknown
-
1999
- 1999-10-12 NO NO994967A patent/NO994967L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CZ299963B6 (en) | 2009-01-07 |
KR20010006460A (en) | 2001-01-26 |
DK0975764T3 (en) | 2005-01-03 |
EP0975764A1 (en) | 2000-02-02 |
WO1998046760A1 (en) | 1998-10-22 |
AU6856398A (en) | 1998-11-11 |
SK285724B6 (en) | 2007-07-06 |
CA2286165C (en) | 2009-02-03 |
ATE275200T1 (en) | 2004-09-15 |
KR100528755B1 (en) | 2005-11-15 |
CZ349399A3 (en) | 2000-02-16 |
JP2001521387A (en) | 2001-11-06 |
DE69825978T2 (en) | 2005-09-15 |
PL196607B1 (en) | 2008-01-31 |
PL336312A1 (en) | 2000-06-19 |
EP0878546A1 (en) | 1998-11-18 |
CA2286165A1 (en) | 1998-10-22 |
EP0975764B1 (en) | 2004-09-01 |
SK142899A3 (en) | 2000-06-12 |
PT975764E (en) | 2004-11-30 |
NO994967D0 (en) | 1999-10-12 |
BR9808542A (en) | 2000-05-23 |
DE69825978D1 (en) | 2004-10-07 |
AU750162B2 (en) | 2002-07-11 |
ES2227822T3 (en) | 2005-04-01 |
NZ500012A (en) | 2001-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vile et al. | The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider | |
ES2256842T3 (en) | VENUE OF ADENOVIRUS RECOMBINANT AND METHODS OF USE. | |
ES8500322A1 (en) | Viruses with recombinant surface proteins. | |
NO994967D0 (en) | Gene delivery vehicles expressing the apoptosis-inducing proteins VP2 and / or apoptin | |
DK0797678T3 (en) | Hybrid adenovirus AAV virus and methods for using it | |
NO20004631L (en) | Compounds and Methods for Therapy and Diagnosis of Lung Cancer | |
ATE520420T1 (en) | RECOMBINANT VIRUS CONTAINING THE TELOMELYSIN-GFP GENE | |
BR0009505A (en) | Lung cancer therapy and diagnosis compounds and processes | |
ATE229977T1 (en) | PEPTIDES WITH ANTIPROLIFERATIVE PROPERTIES | |
DE3585790D1 (en) | VARICELLA ZOSTER VIRUS DNA SEQUENCES, THESE VECTORS AND HOST CELLS, MATCHING POLYPEPTIDES, AND THESE COMPOUNDS. | |
CA2167578A1 (en) | Chicken anemia virus mutants and vaccines and uses based on the viral proteins vp1, vp2 and vp3 or sequences of that virus coding therefor | |
DE69928395D1 (en) | CYCLIN-E2 PROTEINS AND ENCODING GENES | |
ATE349225T1 (en) | APO B, ANNEXIN V AND TUBULIN: MEDICAL AND DIAGNOSTIC USE AND USE FOR PURIFICATION OF HCV | |
DK498387A (en) | Viral DNA SEQUENCE | |
FI950516A0 (en) | Interferon alpha / beta binding protein, its preparation and use | |
HUP0103871A2 (en) | Recombinent celo virus and celo virus dna | |
NO20005321L (en) | Host-encoded protein expressed in Marek's disease (MDV) infected cells and antibodies thereto | |
CO5050254A1 (en) | COMPOUNDS FOR THE TREATMENT AND DIAGNOSIS OF CANCER DE PULMON |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |